becton dickinson compani
summari report stand-alon result
gener better expect rais guidanc
also street expect report ep
beat consensu forecast ep beat vs model
primarili reflect gross margin lower tax rate expect
pro forma ex-fx sale growth includ
headwind us dispens chang hurrican maria impact
bcr compani also rais ep guidanc
ex-fx ex-fx includ
net bcr accret fx tailwind believ
rais guidanc may still conserv includ potenti
increment bcr cost save fx benefit
addit despit higher ep outlook increment
tax rate headwind next year manag continu expect mid-
teen ep growth rais ep estim
increas price target base
ep estim ebitda estim
pro forma sale ex-fx grow vs
ex-fx growth stand-alon compani
guidanc includ us dispens chang
impact hurrican maria bcr believ fx guidanc
tailwind conserv actual benefit may closer
expect bdx pro forma revenu growth acceler
driven easier comp
absenc bcr puerto rico headwind continu
lap us dispens chang see overal
guidanc achiev note possibl out-performance
life scienc especi flu season remain sever and/or last
longer compani expect growth continu low-doubl
digit emerg market includ acceler growth china
pro forma mid-teen
see potenti upsid rais ep guidanc
increas ep guidanc ex-fx
growth ex-fx growth rais guidanc
assum net bcr accret benefit lower tax
rate fx tailwind believ bottom-lin
guidanc could still prove conserv sever reason bcr
cost save could exceed assum guidanc
increment fx tailwind estim anoth
although manag expect reinvest least portion
sever flu season compar last year
estim ad pro forma growth
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
includ bcr acquisit start
compani prioriti stock list
compani data secur llc estim reuter
continu previou page
overal perform better expect report total revenu
consensu estim ex-fx growth better
estim larg reflect out-performance bd life scienc grew ex-fx vs
estim owe earlier start flu season pro forma basi ex-fx sale growth
includ estim headwind us dispens chang
disrupt bcr surgic busi due hurrican maria exclud headwind pro forma
underli growth stand-alon basi report gross margin
well estim oper margin estim
due higher sg spend higher revenu higher gross margin lower tax rate vs
estim contribut ep beat vs our/consensu estim
lutonix solid outlook remain unchang note bcr us peripher vascular sale grew
high-singl digit consist recent growth trend growth driven
recent launch lutonix av arterioven fistula access us indic
perform in-lin expect far compani continu see us av access
market opportun lutonix btk below-the-kne manag expect
follow-up complet end august file fda approv end
studi remain blind understand adapt trial design allow patient
enrol end base predict probabl success differ predetermin target
lutonix btk trial enrol patient ceil suggest us enrol
stop like suffici data posit outcom otherwis enrol
could continu remain cautious optimist lutonix btk trial posit
continu see commerci opportun attract
product launch mostli track launch number new product across
three busi segment far remain track new launch plan figur
note barricor relaunch us also remain track us diabet
end develop insulin pen redeploy resourc
smart patch pump latter expect launch later addit compani continu
expect relaunch infus set earli
becton dickinson compani
ductplan launchiv solut sodium chlorid dextroselaunchedbd healthsight integr platformlaunchedbd pyxi es neopak xsi glass pre-fil syringelaunchedbd phaseal optimafi purehub iv needless connector disinfect capsfi solut addit compoundsfi venflon bd instaflash needl technologyfi accucath catheterbd venflon safeti bd instaflash needl technologyfi launchbd check-point cpo assay ce mark launchedaddit bd optibuild reagent sirigendyeslaunchedbd enter viral panelfi tbfi onclar hpv us pma fy synapsi informat ds platformfi abseq assay protein expressionfi barricor blood collect tube late fy launchallpoint port access systemlaunchedlutonix av catheterlaunchedlifest seri stentfi open fixat systemfi stent graft av access graft indic fy catheterfi posit system ventralight st meshfi long lesion balloon lengthsfor sfa fy compani report secur llcbd medicalbd life sciencesbd intervent medic technolog
updat new ex-fx medic ex-fx life scienc ex-fx intervent ex-fx market ex-fx growth-doubl ex-fx market ex-fx revenu adjust divestitur includ us dispens chang impact hurrican maria bcr sourc compani report secur llc estim stand-alon forma bcr becton dickinson compani
price target
price target base blend ev/ebitda ebitda price-to-earnings
estim risk includ slower expect integr bcr lower expect cost save
accret bcr unexpect delay debt pay unexpect pipelin delay/setback
believ well posit acceler top- bottom-lin growth bcr acquisit
potenti upsid
global medic devic compani oper two key segment medic life
scienc pend bcr acquisit add third leg platform intervent grew
revenu pro forma ex-fx basi
becton dickinson compani fy end sep million except per share data -- stand-alonepro forma bcr qtr life revenu revenu revenu pf product amort expense- gross total oper oper interest incom interest incom gore royalti expir aug incom expens total non-op incom expens pre-tax incom tax expens net prefer dividend net incom common method share outstand method convert share outstand marginsgross op ep method op ep method medic technolog
